1. Jenkin RD, Boesel C, Ertel I et al (1987) Brain-stem tumors in childhood: a prospective randomized trial of irradiation with and without adjuvant CCNU, VCR, and prednisone. A report of the Children’s Cancer Study Group. J Neurosurg 66(2):227–233

2. Hargrave D, Bartels U, Bouffet E (2006) Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol 7:241–248

3. Wells EM, Gaillard WD, Packer RJ (2012) Pediatric brain tumors and epilepsy. Semin Pediatr Neurol 19(1):3–8

4. Tremont-Lukats I, Ratilal B, Armstrong T et al (2008) Antiepileptic drugs for preventing seizures in people with brain tumors. Cochrane Database Syst Rev 16(2):CD004424

5. Weller M, Stupp R, Wick W (2012) Epilepsy meets cancer: when, why, and what to do about it? Lancet Oncol 13(9):e375–e382

6. Kawasaki M, Hernández-Fustes OJ, Machado S, Aguiar LR, Mattar F, Panfilio CB, Hernández-Cossio O (1999) Epilepsia y tumor cerebral. Rev Neurol 28(11):1047–1049

7. Felix FH, de Araujo OL, da Trindade KM et al (2013) Survival of children with malignant brain tumors receiving valproate: a retrospective study. Childs Nerv Syst 29(2):195–197

8. Felix FH, Trompieri NM, de Araujo OL, da Trindade KM, Fontenele JB (2011) Potential role for valproate in the treatment of high-risk brain tumors of childhood-results from a retrospective observational cohort study. Pediatr Hematol Oncol 28:556–570

9. Packer RJ, Lange B, Ater J et al (1993) Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J Clin Oncol 11(5):850–856

10. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8(7):1277–1280

11. Chassot A, Canale S, Varlet P et al (2012) Radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. J Neurooncol 106(2):399–407

12. Brandes AA, Franceschi E, Gorlia T et al (2012) European Organisation for Research and Treatment of Cancer Brain Tumour Group. Appropriate end-points for right results in the age of antiangiogenic agents: future options for phase II trials in patients with recurrent glioblastoma. Eur J Cancer 48(6):896–903

13. Hargrave D, Chuang N, Bouffet E (2008) Conventional MRI cannot predict survival in childhood diffuse intrinsic pontine glioma. J Neurooncol 86(3):313–319

14. Masoudi A, Elopre M, Amini E et al (2008) Influence of valproic acid on outcome of high-grade gliomas in children. Anticancer Res 28(4C):2437–2442

15. Oberndorfer S, Piribauer M, Marosi C et al (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J Neuro-Oncol 72:255–260

16. Wolff J, Kramm C, Kortmann R et al (2008) Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma. J Neurooncol 90(3):309–314

17. Weller M, Gorlia T, Cairncross JG et al (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology 77:1156–1164

18. Guthrie GD, Eljamel S (2012) Impact of particular antiepileptic drugs on the survival of patients with glioblastoma multiforme. J Neurosurg. doi:10.3171/2012.10.JNS12169

19. Barker CA, Bishop AJ, Chang M, Beal K, Chan TA (2013) Valproic acid use during radiation therapy for glioblastoma associated with improved survival. Int J Radiat Oncol Biol Phys 86(3):504–509

20. Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C et al (2008) Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 34(3):206–222

21. Michaelis M, Michaelis UR, Fleming I et al (2004) Valproic acid inhibits angiogenesis in vitro and in vivo. Mol Pharmacol 65(3):520–527

22. Chen Y, Tsai YH, Tseng SH (2012) Valproic acid affected the survival and invasiveness of human glioma cells through diverse mechanisms. J Neurooncol 109(1):23–33

23. Van Nifterik KA, Van den Berg J, Slotman BJ, Lafleur MV, Sminia P, Stalpers LJ (2012) Valproic acid sensitizes human glioma cells for temozolomide and γ-radiation. J Neurooncol 107(1):61–67

24. Paugh BS, Broniscer A, Qu C, Miller CP, Zhang J, Tatevossian RG, Olson JM, Geyer JR, Chi SN, da Silva NS, Onar-Thomas A, Baker JN, Gajjar A, Ellison DW, Baker SJ (2011) Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. J Clin Oncol 29(30):3999–4006

25. Wu G, Broniscer A, McEachron TA, Lu C, Paugh BS, Becksfort J, Qu C, Ding L, Huether R, Parker M, Zhang J, Gajjar A, Dyer MA, Mullighan CG, Gilbertson RJ, Mardis ER, Wilson RK, Downing JR, Ellison DW, Zhang J (2012) Baker SJ; St. Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 44(3):251–253

26. Hummel TR, Wagner L, Ahern C, Fouladi M, Reid JM, McGovern RM, Ames MM, Gilbertson RJ, Horton T, Ingle AM, Weigel B, Blaney SM (2013) A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a children’s oncology group phase 1 consortium study. Pediatr Blood Cancer 60(9):1452–1457

27. Su JM, Li XN, Thompson P et al (2011) Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children’s oncology group report. Clin Cancer Res 17(3):589–597

28. Friedman HS, Krischer JP, Burger P et al (1992) Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized phase II study. J Clin Oncol 10(2):249–256